AQNEURSA (levacetylleucine)
FDA PDUFA Target Action Date · IntraBio Inc.
Saturday, September 19, 2026
Approved
approved Note: Approved 2026-09-18 as AQNEURSA (SUPPL NDA219132). Auto-resolved from data/drugs.json by scripts/pdufa/resolve-outcomes.cjs on 2026-10-06; 1d from the PDUFA date.
Drug Information
- Drug Name
- AQNEURSA (levacetylleucine) (CT.gov)
- Application Type
- sNDA
- FDA Designations
- Priority Review
- Indication
- Ataxia-telangiectasia
- Approved As
- AQNEURSA (levacetylleucine)
Filing Details
- Company
- IntraBio Inc. →
- Source
- BusinessWire →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Explore IntraBio Inc.
View IntraBio Inc.'s full pipeline, approved drugs, and clinical trials.
Data sourced from SEC EDGAR filings. Last updated: 2026-06-29. Report an issue